Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | IDH2 R140Q IDH2 R353H |
Therapy | Enasidenib |
Indication/Tumor Type | leukemia |
Response Type | predicted - resistant |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
IDH2 R140Q IDH2 R353H | leukemia | predicted - resistant | Enasidenib | Preclinical - Biochemical | Actionable | In a preclinical study, Idhifa (enasidenib) did not inhibit Idh2 activity and R-2HG production in a leukemia cell line expressing IDH2 R140Q and R353H in culture (PMID: 36222845). | 36222845 |
PubMed Id | Reference Title | Details |
---|---|---|
(36222845) | Disabling Uncompetitive Inhibition of Oncogenic IDH Mutations Drives Acquired Resistance. | Full reference... |